Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.

Poggesi I, Li LY, Jiao J, Hellemans P, Rasschaert F, de Zwart L, Snoeys J, De Meulder M, Mamidi RNVS, Ouellet D.

Eur J Drug Metab Pharmacokinet. 2020 Feb;45(1):101-111. doi: 10.1007/s13318-019-00581-9.

PMID:
31673875
2.

Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.

De Jonghe S, Johnson MD, Mamidi RNVS, Vinken P, Feyen B, Lammens G, Proctor J.

Chem Biol Interact. 2017 Nov 1;277:85-90. doi: 10.1016/j.cbi.2017.09.008. Epub 2017 Sep 12.

PMID:
28916336
3.

In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

Mamidi RNVS, Dallas S, Sensenhauser C, Lim HK, Scheers E, Verboven P, Cuyckens F, Leclercq L, Evans DC, Kelley MF, Johnson MD, Snoeys J.

Br J Clin Pharmacol. 2017 May;83(5):1082-1096. doi: 10.1111/bcp.13186. Epub 2016 Dec 20.

4.

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.

Devineni D, Murphy J, Wang SS, Stieltjes H, Rothenberg P, Scheers E, Mamidi RN.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):295-304. doi: 10.1002/cpdd.162. Epub 2014 Dec 11.

PMID:
27136910
5.
6.

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.

Devineni D, Manitpisitkul P, Murphy J, Skee D, Wajs E, Mamidi RN, Tian H, Vandebosch A, Wang SS, Verhaeghe T, Stieltjes H, Usiskin K.

Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):226-36. doi: 10.1002/cpdd.166. Epub 2014 Oct 27.

PMID:
27140803
7.

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RN, Weiner S, Wang SS, Ariyawansa J, Stieltjes H, Wajs E, Di Prospero NA, Rothenberg P.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. doi: 10.5414/CP202158.

8.

Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.

Ways K, Johnson MD, Mamidi RN, Proctor J, De Jonghe S, Louden C.

Toxicol Pathol. 2015 Jan;43(1):48-56. doi: 10.1177/0192623314557179. Epub 2014 Nov 14.

PMID:
25398756
9.

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.

Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, Mamidi RN, Tian H, Weiner S, Stieltjes H, Sha S, Rothenberg P.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):41-53. doi: 10.5414/CP202157.

PMID:
25345427
10.

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.

De Jonghe S, Proctor J, Vinken P, Feyen B, Wynant I, Marien D, Geys H, Mamidi RN, Johnson MD.

Chem Biol Interact. 2014 Dec 5;224:1-12. doi: 10.1016/j.cbi.2014.09.018. Epub 2014 Oct 5.

PMID:
25289773
11.

Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.

Mamidi RN, Proctor J, De Jonghe S, Feyen B, Moesen E, Vinken P, Ma JY, Bryant S, Snook S, Louden C, Lammens G, Ways K, Kelley MF, Johnson MD.

Chem Biol Interact. 2014 Sep 25;221:109-18. doi: 10.1016/j.cbi.2014.08.001. Epub 2014 Aug 14.

PMID:
25130857
12.

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, Lim HK.

Drug Metab Dispos. 2014 May;42(5):903-16. doi: 10.1124/dmd.113.056440. Epub 2014 Feb 25.

PMID:
24568888
13.

De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes.

Dallas S, Sensenhauser C, Batheja A, Singer M, Markowska M, Zakszewski C, Mamidi RN, McMillia M, Han C, Zhou H, Silva J.

Curr Drug Metab. 2012 Sep 1;13(7):923-9.

PMID:
22475265
14.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.

PMID:
20661737
15.

Assessing the issue of instability due to Michael adduct formation in novel chemical entities possessing a carbon-carbon double bond during early drug development--applicability of common laboratory analytical protocols.

Polepally AR, Kumar VV, Bhamidipati R, Kota J, Naveed SA, Reddy KH, Mamidi RN, Selvakumar N, Mullangi R, Srinivas NR.

Biomed Chromatogr. 2008 Sep;22(9):960-76. doi: 10.1002/bmc.1015.

PMID:
18683847
16.

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.

Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R.

Cancer Chemother Pharmacol. 2007 Nov;60(6):777-87. Epub 2007 Feb 7.

PMID:
17285316
17.

Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.

Mamidi RN, Mannens G, Annaert P, Hendrickx J, Goris I, Bockx M, Janssen CG, Kao M, Kelley MF, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):566-75. Epub 2007 Jan 12.

PMID:
17220243
18.

Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.

Singh SK, Vobbalareddy S, Kalleda SR, Casturi SR, Datla SR, Mamidi RN, Mullangi R, Ramanujam R, Yeleswarapu KR, Iqbal J.

Bioorg Med Chem. 2006 Dec 15;14(24):8626-34. Epub 2006 Sep 1.

PMID:
16949828
19.

Cell-based models to study hepatic drug metabolism and enzyme induction in humans.

Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W, Mannens G.

Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):75-90. Review.

PMID:
16922654
20.

Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey.

Hemeryck A, Mamidi RN, Bottacini M, Macpherson D, Kao M, Kelley MF.

Xenobiotica. 2006 Jul;36(7):597-613.

PMID:
16864506
21.

Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.

Chatterjee A, Digumarti R, Katneni K, Upreti VV, Mamidi RN, Mullangi R, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Srinivas NR.

J Clin Pharmacol. 2005 Apr;45(4):453-60.

PMID:
15778426
22.

HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats.

Mullangi R, Kallem RR, Bhamidipati RK, Mamidi RN, Srinivas NR.

Biomed Chromatogr. 2004 Oct;18(8):576-80.

PMID:
15386513
23.
24.

2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.

Singh SK, Vobbalareddy S, Kalleda SR, Rajjak SA, Casturi SR, Datla SR, Mamidi RN, Mullangi R, Bhamidipati R, Ramanujam R, Akella V, Yeleswarapu KR.

Org Biomol Chem. 2004 Sep 7;2(17):2442-50. Epub 2004 Aug 11.

PMID:
15326524
25.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study.

Chatterjee A, Digumarti R, Mamidi RN, Katneni K, Upreti VV, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Subramaniam S, Srinivas NR.

J Clin Pharmacol. 2004 Jul;44(7):723-36.

PMID:
15199077
26.

Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.

Mamidi RN, Benjamin B, Ramesh M, Srinivas NR.

Biomed Chromatogr. 2003 Sep;17(6):417-20.

PMID:
13680854
27.

Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics.

Upreti VV, Mamidi RN, Katneni K, Srinivas NR.

Biomed Chromatogr. 2003 Sep;17(6):385-90.

PMID:
13680849
28.

Bioanalytical considerations for compounds containing free sulfhydryl groups.

Srinivas NR, Mamidi RN.

Biomed Chromatogr. 2003 Jul;17(5):285-91. Review.

PMID:
12884392
29.

Oral bioavailability and pharmacokinetics of DRF-4367, a new COX-2 inhibitor in rats.

Ramesh M, Mamidi RN, Jagannath K, Singh SK, Rao KS, Rao YK, Seshagirirao C, Rajagopalan R, Srinivas NR.

Eur J Drug Metab Pharmacokinet. 2003 Apr-Jun;28(2):137-41.

PMID:
12877572
30.

Quantitative determination of ragaglitazar in rat plasma by HPLC: validation and application in pharmacokinetic study.

Kota J, Mullangi R, Mamidi RN, Rajagopalan R.

Biomed Chromatogr. 2002 Dec;16(8):495-9.

PMID:
12474210
31.

Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats.

Mamidi RN, Katneni K, Mullangi R, Ramanujam R.

Eur J Drug Metab Pharmacokinet. 2002 Jul-Sep;27(3):175-8.

PMID:
12365198
32.

Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.

Mamidi RN, Mullangi R, Kota J, Bhamidipati R, Khan AA, Katneni K, Datla S, Singh SK, Rao KY, Rao CS, Srinivas NR, Rajagopalan R.

Biopharm Drug Dispos. 2002 Oct;23(7):273-82.

PMID:
12355578
33.

Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones.

Selvakumar N, Srinivas D, Khera MK, Kumar MS, Mamidi RN, Sarnaik H, Charavaryamath C, Rao BS, Raheem MA, Das J, Iqbal J, Rajagopalan R.

J Med Chem. 2002 Aug 29;45(18):3953-62.

PMID:
12190317
34.

HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study.

Mamidi RN, Chaluvadi MR, Benjamin B, Ramesh M, Katneni K, Babu AP, Bhanduri J, Rao NM, Rajagopalan R.

Arzneimittelforschung. 2002;52(7):560-4.

PMID:
12189780
35.

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.

Madhavan GR, Chakrabarti R, Vikramadithyan RK, Mamidi RN, Balraju V, Rajesh BM, Misra P, Kumar SK, Lohray BB, Lohray VB, Rajagopalan R.

Bioorg Med Chem. 2002 Aug;10(8):2671-80.

PMID:
12057656
36.

Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.

Madhavan GR, Chakrabarti R, Kumar SK, Misra P, Mamidi RN, Balraju V, Kasiram K, Babu RK, Suresh J, Lohray BB, Lohrayb VB, Iqbal J, Rajagopalan R.

Eur J Med Chem. 2001 Jul-Aug;36(7-8):627-37.

PMID:
11600232
37.

Polymorphism of dextromethorphan oxidation in South Indian subjects.

Mamidi RN, Satyavageeswaran S, Vakkalanka SV, Chaluvadi MR, Katneni K, Brahmadevara N, Damodarram G, Subramaniam S.

Clin Pharmacol Ther. 1999 Aug;66(2):193-200.

PMID:
10460073
38.

Oral bioavailability and pharmacokinetics of the new insulin sensitizer DRF-2189 in Wistar rats.

Jajoo HK, Mamidi RN, Vakkalanka SV, Sathyavageeswaran S, Katneni K, Ayalasomayajula PS, Rao BP, Lohray BB, Subramaniam S.

Arzneimittelforschung. 1999 Feb;49(2):133-6.

PMID:
10083982
39.

Novel euglycemic and hypolipidemic agents. 1.

Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Mamidi RN, Jajoo HK, Subramaniam S.

J Med Chem. 1998 May 7;41(10):1619-30.

PMID:
9572887
40.

Characterization of clofazimine metabolites in humans by HPLC-electrospray mass spectrometry.

Krishna DR, Mamidi RN, Hofmann U, Prabhakar CM.

Arzneimittelforschung. 1997 Mar;47(3):303-6.

PMID:
9105550

Supplemental Content

Loading ...
Support Center